

29th of March 2022

Dear Healthcare Professional,

ClopineCENTRAL™ Website Updates:

Douglas would like to advise you of the new improvements occurring on the ClopineCENTRAL™ website effective 28th of March 2022 as implemented and administered by Pfizer.

Summary:

Patient Registration	We have simplified and reduced to 3 registration questions only and will no longer ask for the patient weight
Patient Administration page	The Recommended Tests Consent are no longer available for input.
Adding Blood Test Results	You can now select the name of the medicine, Clopine* tablet or suspension. If required, you must enter Patient Notes separately.
Therapy Event	The reason options have been consolidated. If you prefer, you can choose to write your own reason other than the ones listed in the drop-down please select "Other". We now ask for your consent to be contacted by the Douglas Drug Safety team about the therapy event.
Override	Doctor & Coordinator user on behalf of the doctor will need to approve the overrides to reflect on the patient administration page, or the information will be voided after 72 hours.
Recommended Tests & Patient Assessments	These fields are no longer available for input, you can only view and not edit any existing information.
'Green' and 'Amber' Reference Range calculations	These range calculations have been aligned to the Data Sheet. There is no change to supporting processes or notifications that are triggered by blood test results. The product information can be accessed for both Clopine* and Versacloz™ on Information for Prescribers/Consumers Search (Medsafe.govt.nz)

We have attached the updated copy of the ClopineCENTRAL™ protocol booklet and website manual to support the new improvements.

Further information and recommendations to healthcare professionals

For more information and support on any of the above improvements, please contact the ClopineCENTRAL™ team on 1800 656 403 or clopinecentral@pfizer.com

Sincerely,



Roger Smart
Regulatory and Clinical Affairs Strategic Business Partner

29th of March 2022

Please review the Full Datasheet at www.medsafe.govt.nz. Before prescribing Clopine* or Versacloz™ (clozapine), physicians must be registered with a monitoring program and comply with the relevant safety measures. Mandatory haematological monitoring is required.

* Clopine is a registered trademark in New Zealand and other countries.